A Double-Blind, Randomized, Parallel, Controlled, Study to Compare Pharmacokinetics and Pharmacodynamics of BP13 (filgrastim) with EU-approved Neupogen in Healthy Male Adult Subjects
Latest Information Update: 12 Mar 2022
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms BP13-101
- Sponsors CURATEQ BIOLOGICS PRIVATE LIMITED
- 19 Dec 2020 New trial record